Lenzilumab for Compassionate Use

Humanigen is now accepting enquiries regarding lenzilumab for compassionate use.

Compassionate use, also known as expanded access, provides a potential pathway for a patient with an immediately life-threatening serious disease or condition to gain access to an investigational medical product (drug, biologic, or medical device) for treatment outside of clinical trials when no comparable or satisfactory alternative therapy options are available. For more information, please refer to the FDA guidelines for patients, physicians and industry.

 

Humanigen is also planning a Phase III clinical trial to evaluate lenzilumab for the prevention and treatment of cytokine storm arising from COVID-19, which can lead to acute respiratory distress syndrome (ARDS) and/or death in some patients.

 

Enquiries regarding compassionate use should be directed to

HumanigenCompassionateUse@ctifacts.com

  • Twitter

©2020 Humanigen, Inc.  All rights reserved